Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2026. The company reported a net loss of $4.88 million for the third quarter of 2026, a significant improvement from a net loss of $15.74 million in the same period of 2025. For the nine-month period, the net loss was $21.40 million, down from $30.48 million in 2025. Total assets and liabilities both decreased compared to the end of the previous fiscal year. The company generated $100,000 in licensing revenue during the period. However, the report highlights substantial doubt about the company's ability to continue as a going concern, stating that additional financing is required to fund operations beyond the first quarter of 2027.

Dogwood Therapeutics reported a net loss of $11.5 million, or $0.34 per share, for the second quarter ended June 30, 2026. The company recognized a significant non-cash IPR&D impairment charge of $9.2 million. Despite the loss, Dogwood provided positive updates on its clinical pipeline, including the Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathy being on track for top-line results in fall 2026, and the commencement of a long-term extension study. Additionally, the company announced a worldwide development and commercialization partnership for legacy antiviral assets with a potential value of up to $100 million.

Dogwood Therapeutics announced its Q2 2026 financial results, reporting a net loss of $11.5 million, significantly higher than the $3.8 million loss in Q2 2025, primarily due to a $9.2 million non-cash IPR&D impairment charge. Operationally, the company confirmed its Halneuron® Phase 2b trial is on track for top-line results in Fall 2026, with 217 patients enrolled, and commenced a long-term extension study. Additionally, SP16 received IND approval, and Dogwood secured a worldwide development and commercialization partnership for antiviral assets with a potential value of up to $100 million. The company also appointed Iain Dukes as Chair of its Scientific Advisory Board and has $9.6 million in cash, providing an operational runway through Q4 2026.

Dogwood Therapeutics, Inc. announced the appointment of Iain Dukes, Ph.D., as Chair of its newly formed Scientific Advisory Board (SAB). Dr. Dukes, a veteran biopharma industry executive and OrbiMed partner, will advise the company on scientific developments for its pipeline. Dogwood is advancing Halneuron® in Phase 2b for chemotherapy-induced neuropathic pain, with data expected in Fall 2026, and SP16 into Phase 1b for chemotherapy-induced peripheral neuropathy.

Dogwood Therapeutics held its Annual Meeting on June 16, 2026, where stockholders approved all proposals. Key approvals included an amendment to the Certificate of Incorporation to increase authorized common and preferred stock, the election of seven directors, and the ratification of Forvis Mazars, LLP as the independent auditor for 2026. Stockholders also approved the compensation of named executive officers and opted for an annual advisory vote on executive compensation.

Dogwood Therapeutics announced the commencement of a new 12-week open-label extension study for Halneuron , its non-opioid medicine for chemotherapy-induced neuropathic pain (CINP). This study will assess safety and efficacy over an additional three months, with data bolstering the planned Phase 3 development program submission to the FDA, projected for the first half of 2027. The ongoing 4-week double-blinded Phase 2b study showed a positive interim assessment, with a low dropout rate under 5%, and is expected to release top-line results in fall 2026.

Dogwood Therapeutics reported a net loss of $(4.99) million for Q1 2026, an improvement from $(10.92) million in Q1 2025, with basic and diluted net loss per share improving to $(0.15). Despite an increase in cash and cash equivalents to $13.23 million, the company disclosed substantial doubt about its ability to continue as a going concern beyond Q4 2026 without additional financing. Operating expenses increased to $5.08 million, and the company continues to advance its drug candidates, with Halneuron® Phase 2b results expected in Fall 2026.

Dogwood Therapeutics announced its first quarter 2026 financial results, reporting a net loss attributable to common stockholders of $5.0 million, or $(0.15) per share. The company highlighted significant pipeline progress, with its Halneuron® Phase 2b trial on track for top-line results in fall 2026 and FDA acceptance of the SP16 IND Application. Additionally, Dogwood executed a worldwide development and commercialization partnership for legacy antiviral assets, with a potential value of up to $100 million.

Dogwood Therapeutics announced Q1 2026 financial results, reporting a net loss of $5.0 million, a significant improvement from $12.2 million in Q1 2025. The company achieved key pipeline milestones, including FDA acceptance of the SP16 Investigational New Drug Application for chemotherapy-induced pain and neuropathy, with enrollment starting mid-2026. Its lead candidate, Halneuron, remains on track for top-line Phase 2b results in fall 2026 for chemotherapy-induced neuropathic pain. Additionally, Dogwood secured a worldwide development and commercialization partnership for legacy antiviral assets, potentially valued up to $100 million for the company and its shareholders.

Dogwood Therapeutics, Inc. (DWTX) announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026. Key proposals include the election of seven director nominees, ratification of Forvis Mazars, LLP as the independent auditor, and an amendment to increase authorized common and preferred stock. Stockholders will also cast advisory votes on the frequency of future executive compensation votes and on named executive officer compensation.